Spelling suggestions: "subject:"healthcare costs"" "subject:"healthecare costs""
51 |
Aferição de custos em unidades básicas de saúde: revisão integrativa da literatura / Cost analysis in primary health care services: an integrative literature reviewCastro, Paula de Sousa e 14 June 2011 (has links)
O objetivo deste estudo foi analisar, a partir da revisão integrativa da literatura nacional, o conhecimento cientifico sobre a aferição de custos em unidades básicas de saúde. Para a coleta de dados realizou-se um levantamento bibliográfico, com busca online, nas bases de dados Portal de Evidências da Biblioteca Virtual em Saúde (BVS), LILACS, Banco de teses USP, Google. A amostra desta pesquisa foi constituída por 10 trabalhos. Os locais estudados foram compostos por municípios de todo o território nacional, com população de 5 mil a mais de 1 milhão de habitantes. Os resultados mostraram que o método mais utilizado (80%) foi a aferição de custos por absorção. Os resultados dos estudos não puderam ser comparados devido à aplicação de conceitos e métodos de aferição de custos com interpretações diversas pelos autores. No entanto, citamos alguns dados aferidos nesses trabalhos. O custo mensal per capita variou de R$ 3,27 a R$ 10,99. As equipes de saúde da família ampliadas com odontólogo podem ter custos até 77,7% maiores que as equipes básicas. Os municípios podem arcar com até 90% dos gastos totais em saúde. Dos custos totais, os gastos com recursos humanos representam em média 75%. Dos trabalhos que aferiram o custo por procedimento os valores variaram de R$ 8,35 a R$ 34,20. Este trabalho mostrou a importância da aplicação de um sistema de custeio na atenção básica, para identificar os principais custos e otimizá-los, buscando melhorar a eficiência e eficácia dos serviços de saúde. Recomenda-se para trabalhos futuros a utilização correta dos princípios dos sistemas de custeio pelos autores, buscando aprimorar a utilização de 9 ferramentas para o gerenciamento de custos na atenção primária à saúde e possibilitando comparações. / This study aimed to analyze, through an integrative review of the Brazilian literature, scientific knowledge about the measurement of costs in primary health care services. An online literature search was carried out for data collection, in the databases Evidence Portal of the Virtual Health Library (VHL), LILACS, University of São Paulo bank of theses and Google. The sample consisted of 10 studies. The study sites were various cities across Brazil, with populations ranging from 5 thousand to over 1 million inhabitants. Results showed that the most used method (80%) was absorption costing. The results of the studies could not be compared due to the use of concepts and methods for measuring costs with different interpretations by the authors. However, the study presents some data obtained in these studies. The monthly cost per capita ranged from R$ 3.27 to R$10.99. Family health teams with dentists may cost up to 77.7% more than the basic teams. Cities can afford up to 90% of total spending on health care. Expenses on human resources account for an average of 75% of the total costs. Of the studies which measured the cost per procedure, values ranged from R$ 8.35 to R$ 34.20. This study showed the importance of applying a costing system in primary health care, in order to identify the main costs and optimize them, seeking to improve the efficiency and effectiveness of health care services. The correct use of the principles of costing systems by the authors is recommended for future studies, as to enhance the use of tools for cost management in primary health care and to enable comparisons.
|
52 |
Estilo de vida de trabalhadores, absenteísmo e gastos com serviços de saúde / Lifestyle factors, sick leave and health care costsRabacow, Fabiana Maluf 03 February 2015 (has links)
Este estudo objetivou analisar a relação entre estilo de vida e absenteísmo e a relação entre estilo de vida e gastos com serviços de saúde em trabalhadores de uma empresa de viação aérea. Foi realizado um estudo longitudinal retrospectivo que avaliou 2201 trabalhadores de uma companhia aérea em São Paulo, SP. Os desfechos de interesse foram absenteísmo por doença e gastos com serviços de saúde. As variáveis independentes obtidas por entrevista foram sexo, idade, nível educacional, tipo de trabalho, estresse e fatores relacionados ao estilo de vida (índice de massa corporal, atividade física e tabagismo). Além disso, o risco para doenças coronarianas foi estimado com base nas medidas de pressão arterial, colesterol e níveis de glicemia. O número de dias de absenteísmo durante os 12 meses de seguimento foi obtido junto aos registros da companhia aérea e as informações sobre gastos com serviços de saúde foram obtidas junto à operadora de saúde responsável pelo plano de saúde dos funcionários da empresa. Foi realizada regressão logística para determinar a influência das variáveis sócio-demográficas, tipo de trabalho e estilo de vida no absenteísmo e regressão linear multivariada para estudar a associação das as variáveis independentes com gastos diretos com saúde e indiretos com absenteísmo. Durante os 12 meses de seguimento do estudo, 53.5% dos sujeitos tiveram pelo menos um episódio de afastamento por doença e entre esses, a média de absenteísmo foi de 8.3 dias de trabalho. A média de gastos por trabalhador com serviços de saúde foi de US$505. Tanto absenteísmo quanto gastos com saúde foram maiores em mulheres. Após ajuste pelas variáveis sócio demográficas, tabagismo foi associado a maior absenteísmo e excesso de peso foi associado a maiores gastos com saúde. Estes resultados reforçam a importância de ações de promoção de saúde que estimulem uma dieta saudável, atividade física e cessação do tabagismo na população estudada, a fim de controlar absenteísmo e reduzir gastos com serviços de saúde / This study aimed to analyze the relationships among lifestyle-related factors with sick leave and health care costs in workers of a Brazilian airline company. In this longitudinal study with one-year follow-up among 2201 employees of a Brazilian airline company, sick leave and health care costs were the primary outcomes of interest. Independent variables collected by interview at enrolment in the study were gender, age, educational level, type of work, stress, and lifestyle related factors (body mass index, physical activity and smoking). In addition, the risk for coronary heart disease was determined based on measurement of blood pressure, total cholesterol and glucose levels. Total number of days on sick leave during 12 months follow-up was available from the company register and information about health care costs was obtained from the health care insurance. Logistic regression analysis was used to determine the influence of socio-demographic, type of work and lifestyle-related factors on sick leave, and multivariate linear regression analysis was performed to study the association of health care costs with the independent variables. During the 12 month follow-up period, 53.5% of the subjects had at least one sickness absence episode and among them, the average sick leave was 8.3 workdays. The average expenditures per worker with health care was US$505. Both sick leave and health care costs were higher among women. After adjustment by socio-demographic variables, smoking was determinant for more days of sick leave and excess weight was determinant for higher health care costs. Physical inactivity was not associated with sick leave or health procedures total costs, but it was associated with higher odds for hospitalization. These results suggest that healthy diet, physical activity and anti-tobacco actions are important targets for health promotion in this study population, in order to reduce health care costs and productivity loss costs
|
53 |
Análise de custo-efetividade do tratamento medicamentoso em hipertensos / Analysis of cost-effectiveness of drug treatment in hypertensive patientsTsuji, Rosana Lima Garcia 10 October 2007 (has links)
INTRODUÇÃO: A hipertensão é um importante problema de saúde pública e os estudos de Custo-Efetividade (C/E) do tratamento antihipertensivo são raros no Brasil. OBJETIVO: Realizar análise farmacoeconômica retrospectiva do tipo C/E do tratamento medicamentoso em hipertensos. MATERIAL E MÉTODOS: Foi analisado o custo (C) dos medicamentos anti-hipertensivos, do número de visitas médicas não programadas e do tratamento dos efeitos adversos e a efetividade (E) medida pela redução média da pressão arterial em mm Hg ao término de estudo sobre eficácia do tratamento Tradicional iniciado com hidroclorotiazida e atenolol comparado ao tratamento Atual iniciado com losartan e anlodipino, administrados aleatoriamente durante 12 meses a hipertensos sem outras doenças concomitantes pertencentes ao estágios 1 e 2 (grupo HT1-2 = 140 menor ou igual PAS < 180 e 90 menor ou igual PAD < 110 mm Hg) e ao estágio 3 (grupo HT3 = PAS > 180 e PAD > 110 mm Hg). RESULTADOS: A razão C/E (R$/mm Hg) no grupo HT1-2 (n = 231) para PAS/PAD dos tratamentos Atual e Tradicional foi de 112,52 ± 395,28 / 181,26 ± 358,91 e 43,05 ± 50,73 / 80,51 ± 108,31 (p < 0,05) ao passo que no grupo HT3 (n = 132) foi de 115,12 ± 254,87 / 108,14 ± 82,56 e 218,59 ± 891,93 / 173,97 ± 447,23 (p > 0,05). CONCLUSÃO: O tratamento Tradicional foi custo-efetivo em relação ao Atual nos hipertensos estágios 1 e 2. Por outro lado, nos hipertensos estágio 3 não houve diferença na razão C/E entre os tratamentos. Estes resultados foram confirmados quando foi utilizado o menor preço de aquisição dos medicamentos e quando foram considerados somente os pacientes que atingiram o controle da pressão arterial ao final do estudo. / INTRODUCTION: Hypertension is an important public health problem and Cost-Effectiveness (C/E) studies of antihypertensive drug treatment are uncommon in Brazil. OBJECTIVE: To perform a cost-effectiveness (C/E) ratio retrospective pharmacoeconomic analysis of drug treatment in hypertensive patients. MATERIAL AND METHODS: Antihypertensive medication cost (C) was analysed, along with the number of non-scheduled medical visits, treatment of adverse effects, and effectiveness (E) based on the average reduction of arterial blood pressure measured in mm Hg at the end of the study comparing the efficacy of a Traditional Treatment with hydrochlorothiazide and atenolol versus Current Treatment using losartan and amlodipine, administered at random for 12 months to hypertensive patients with no other simultaneous diseases and presenting disease stage 1 and 2 (HT1-2 Group = 140 < or = SBP < 180 and < or = 90 DBP < 110mmHg) and stage 3 (HT3 Group = SBP maior or = 180 and DBP > or = 110mmHg). RESULTS: The C/E ratio (R$/mmHg) in the HT1-2 Group (n=231), based on SBP/DBP, for Current and Traditional Treatments was 112.52 ± 395.28 / 181.26 ± 358.91 and 43.05 ± 50.73 / 80.51 ± 18.31 (p < 0.05), while in the HT3 Group (n=132), 115.12 ± 254.87 / 108.14 ± 82.56 and 218.59 ± 891.93 / 173.97 ± 447.23 (p>0.05). CONCLUSION: Traditional treatment was more cost-effective compared to the Current therapy in hypertensive patients with disease stages 1 and 2. On the other hand, in hypertensive patients with disease stage 3 there was no difference in C/E ratio between the treatment regimens. These results were confirmed by using the lowest purchase price of medication and by considering only patients that reached control of their blood pressures at the end of the study.
|
54 |
Análise do custo da internação dos pacientes com AIDS, em um hospital de média complexidade em Porto Alegre, RS / Costs analysis of inpatient stay for AIDS patients’ admissions in a medium-complexity hospital in Porto Alegre, BrazilAbreu, Claudia de Souza Pereira 10 August 2009 (has links)
Made available in DSpace on 2015-03-05T20:06:23Z (GMT). No. of bitstreams: 0
Previous issue date: 10 / Nenhuma / Os hospitais e os demais operadores da saúde estão preocupados com o seu déficit econômico mensal ou anual e precisam reverter essa situação. Entretanto, a questão não é simples de ser equacionada, e a solução passa pela busca de saber o quanto custa o serviço. O presente estudo teve por objetivo avaliar o custo médio da internação de pacientes portadores de HIV/AIDS, em um hospital de média complexidade no município de Porto Alegre – RS e a sua relação com a tabela de remuneração do Sistema único de Saúde (SUS) para estas internações. Foi realizado um estudo observacional descritivo com os pacientes internados na Unidade 2 (Unidade de internação exclusiva de pacientes portadores do vírus HIV/AIDS, com 40 leitos) da Associação Hospitalar Vila Nova (AHVN). A AHVN é um hospital geral que possui 296 leitos e no período da pesquisa (setembro a novembro de 2008) registrou 300 pacientes internados na Unidade em estudo (2.585 diárias). Foram obtidos os custos diretos e indiretos no período de três meses visando o cá / Hospitals and other health institutions have been worried with theirs monthly or annual economic deficit and need to revert this situation. However, this is not a simple matter to solve and the starting point to do so is to know how much the service costs. The objective of this study is to evaluate the average cost of the inpatient stay for patients with HIV/AIDS in a medium-complexity hospital in Porto Alegre – RS and its relationship with the remuneration schedule of SUS (Single Health System) for these inpatient stays. We developed a descriptive observational study with the patients from the Unity 2 (unity with 40 hospital beds exclusive for patients with HIV/AIDS) of the Associação Hospitalar Vila Nova (AHVN). The AHVN is a general hospital with 296 hospital beds and during the time of the research (September to November, 2008) 300 patients were registered in the Unity (2585 inpatient stays). The direct and indirect costs were obtained during three months aiming the calculation of the total cost of the in
|
55 |
Análise de custo-efetividade de esquemas quimioterápicos no tratamento do câncer colorretal metastático sob a perspectiva de um hospital público de ensino / Cost-effectiveness analysis of chemotherapy regimens in the treatment of metastatic colorectal cancer from the perspective of a public teaching hospitalUngari, Andrea Queiróz 14 December 2015 (has links)
Na última década, houve uma significativa melhora nas taxas de resposta, sobrevida livre de progressão e sobrevida global no tratamento do câncer colorretal metastático, resultante do desenvolvimento de novas combinações de quimioterapia padrão e surgimento de drogas alvo-específicas. Considerando o alto custo das terapias e os recursos disponíveis cada vez mais limitados para a atenção à saúde, este estudo teve como objetivo realizar uma análise de custo-efetividade do protocolo XELOX isoladamente (estratégia 1) em comparação ao XELOX acrescido de bevacizumabe (estratégia 2) em tratamento de 1ª linha para pacientes com câncer colorretal metastático sob a perspectiva de um hospital público voltado para a assistência e o ensino. Trata-se de uma avaliação econômica completa do tipo custo-efetividade, empregando-se árvore de decisão simples associada a Modelo de Markov. Os custos foram expressos em unidade monetária local (R$) e os desfechos em meses de vida ganhos. Para a construção do modelo, foi utilizado o software TreeAge Pro 2013®. Foi elaborado um modelo de estados de transição de Markov, em horizonte temporal de 60 meses, sendo que cada ciclo do modelo correspondeu a três meses. Os dados de custos foram coletados retrospectivamente, por microcusteio, e obtidos por meio do sistema interno de dados eletrônico do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Os dados de efetividade e as probabilidades de transição entre os estados de saúde foram calculados utilizandose dados de estudos clínicos selecionados por revisão sistemática. A diferença incremental em meses de vida ganhos foi de 2,25 para um custo extra de R$47 833,57, o que resultou em uma razão de custo-efetividade incremental de R$21 231,43 por mês de vida ganho. Considerando-se um limiar de custo-efetividade de três vezes o valor do Produto Interno Bruto per capita, segundo recomendação da Organização Mundial de Saúde, a adição de bevacizumabe ao esquema XELOX não foi considerada custo-efetiva. Pela análise de sensibilidade, a variável que causou maior impacto foi a efetividade para o estado de saúde \"suporte clínico\" na estratégia 1. Quando este parâmetro foi inserido no modelo com o valor mínimo e o valor máximo, apresentou uma razão de custo-efetividade incremental de R$7 814,47 e R$- 29 614,12 respectivamente. Assim, a estratégia 2 tornou-se dominada pela estratégia 1 / In the last decade, significant improvements have been made in response rates, progression-free survival, and overall survival in the treatment of metastatic colorectal cancer. These improvements are a result of the development of new combinations of standard chemotherapy and new specific targeting drugs. In light of cost of therapies and increasingly limited resources in health care, this study aimed to compare the costeffectiveness of first-line XELOX alone (strategy 1) with XELOX with bevacizumab (strategy 2) in metastatic colorectal cancer patients, in a public hospital which provides education and health care delivery. We conducted a comprehensive economic, costeffectiveness analysis, using the simple decision tree and the Markov model. The costs were expressed in local currency (BRL) and the outcomes in months of life gained. A Markov state transition model was developed over a 60-month time horizon, using a three-month cycle. The model was created using the TreeAge Pro 2013®. Data of costs were collected retrospectively, using the micro-costing method, from the electronic data system of the General Hospital of Ribeirão Preto Medical School of the University of São Paulo. Data of effectiveness and transition probabilities between health states were calculated using data of clinical trials selected in a systematic review. The incremental difference in months of life gained was 2.25 for an extra cost of BRL47,833.57, resulting in an incremental cost-effectiveness ratio of BRL21,231.43 per month of life gained. Considering a cost-effectiveness threshold three times the gross domestic product per capita, following the World Health Organization\'s recommendations, the addition of bevacizumab to XELOX was not considered costeffective. By sensitivity analysis, the highest impact was caused by the variable effectiveness for the health state \"clinical support\" in strategy 1. When this parameter was inserted in the model using the minimum and maximal values, the incremental cost-effectiveness ratio were R$7,814.47 and R$-29,614.12 respectively, indicating that strategy 2 was dominated by the strategy 1
|
56 |
"Gastos elevados na assistência médico-hospitalar de um plano de saúde" / A health insurance's high medical expendituresKanamura, Alberto Hideki 01 December 2005 (has links)
Administradores de saúde estão preocupados com a persistente elevação dos gastos com saúde. Um problema econômico, social e médico. Objetivando estudar as características das pessoas que produzem gastos elevados com saúde, tomou-se a população de um plano de saúde, identificou-se 1% dos casos que mais gastaram com assistência médico-hospitalar e analisou-se a distribuição por idade, sexo, natureza dos gastos, diagnósticos e o impacto no custo do plano. Os resultados revelaram que a idade é importante fator associado ao gasto elevado, que materiais e medicamentos constituíram a maior fração do gasto e os diagnósticos associados mais freqüentes foram doenças do aparelho circulatório e neoplasias malignas. A fração selecionada de 1% foi responsável por 36,2% da despesa e gastaram em média 56,3 vezes mais que os demais / Healthcare managers are concerned with the persistent increasing of healthcare expenditure. An economics, social and medical problem. The objective of this study was to know the characteristics of the population that could predict high medical expenditure. It was selectec the 1% of customers (assisted by an healthcare plan) that generated the highest expenditures. The distribution by age, sex, kind of expenditure, diagnoses and the impact in insurance cost were analyzed. The results showed that the age is important associated factor, medical supplies and drugs were mainly responsible for expenditure. The main diagnose associated with high expenditure were circulatory diseases and cancer was the second. The 1% selected customers generated 36.2% of the total expenditure of their healthcare plan, and spent 56.3 times more than others customers, on average
|
57 |
Scaphoid fractures : Studies on diagnosis and treatmentVinnars, Bertil January 2008 (has links)
Scaphoid fracture is most common in young individuals of working age. Without adequate diagnosis and treatment, long-term results are poor. Operative treatment is being recommended increasingly often instead of a long time in cast, although there is no evidence-based support for its superiority. The present thesis focuses on diagnostic problems and therapeutic consequences of acute scaphoid fractures and of scaphoid reconstruction when other treatments have failed. Simultaneous plain radiographs and computed tomography were done in 97 injured wrists. Structural assessments of plain radiography images were highly predictive with respect to the risk of having a displaced or comminute fracture as diagnosed on computed tomography. Any finding of a gap or step-off > 0.5 mm, the presence of an intermediate fragment or a dorsal lunate tilt of ≥ 15° identified 81 % of fractures that were displaced or comminuted when investigated with computed tomography. Eighty-three patients were randomly allocated to and received either nonoperative treatment in cast or operative treatment with the aim of assessing long-term outcome of the two treatment options. Fifty-two of the patients were occupationally active. From an occupational perspective with an early return to work, surgical treatment was superior in individuals with manual employment, and from a health economic perspective conservative treatment was superior in non-manual workers. Patients treated for scaphoid fractures generally do well up to 13 years after the injury based on limb-specific outcome scores. No benefits were identified with operative treatment compared to non-operative treatment in cast. On the contrary, there was an increased risk for osteoarthritis in the scaphotrapezial joint in those who were operated. The patient-rated long-term results of silicone implant arthroplasty were good, with pain relief and reasonable hand function in many patients up to 20 years after surgery.
|
58 |
Les coûts des soins de santé chez les personnes âgées de 65 ans et plus avec incapacités au QuébecBoissonneault, Michaël 06 1900 (has links)
La question des coûts des soins de santé gagne en intérêt dans le contexte du vieillissement de la population. On sait que les personnes en moins bonne santé, bien que vivant moins longtemps, sont associées à des coûts plus élevés. On s'intéresse aux facteurs associés à des coûts publics des soins de santé plus élevés au niveau individuel, chez les Québécois vivant en ménage privé âgés de 65 ans et plus, présentant au moins un type d’incapacité. À l’aide de modèles de régression, la variation des coûts pour la consultation de professionnels de la santé et la prise de médicaments a été analysée en fonction du nombre d’incapacités ainsi que de la nature de celles-ci. Les informations sur l’état de santé et la situation socio-démographique proviennent de l’Enquête sur les limitations d’activités (EQLA) de 1998, celles sur les coûts du Fichier d’inscription des personnes assurées (FIPA) de la Régie de l’Assurance maladie du Québec (RAMQ), pour la même année. Les résultats montrent que les deux types de coûts considérés augmentent en fonction du nombre d’incapacités. D’autre part, des coûts plus élevés ont été trouvés chez les personnes présentant une incapacité liée à l’agilité concernant la consultation de professionnels de la santé, alors que, concernant la prise de médicaments, le même constat s’applique aux personnes avec une incapacité liée à la mobilité. Les deux types de coûts considérés présentent un niveau plus élevé chez les personnes présentant une incapacité liée au psychisme, en particulier lorsque l’on considère la prise de médicaments. Ces observations soulignent l’intérêt de considérer la nature du problème de santé lorsque l’on étudie les déterminants individuels du niveau des coûts des soins de santé. / The issue of healthcare costs becomes more pertinent in the current context of an ageing population. Despite the fact that elderly people in poor health do not live as long as those in good health, they are associated with higher healthcare costs. The purpose of this paper is to investigate the factors related to the variations of the public healthcare costs at an individual level, for non-institutionalized people of 65 years and older, living in the province of Quebec with at least one type of disability. Log-linear multiple regression models were performed, with physician consultations costs and medication costs as dependent variables. The number of disabilities an individual has, the type of disability, and the main socio-demographic confounders were chosen as independent variables. Information on these independent variables was taken from the 1998 survey Enquête Québécoise sur les Limitations d’Activités, and information on the dependent variables was taken from the dataset of Quebec’s public health insurance program from the same year. Both physician consultation and medication costs were found to be a function of the number of disabilities an individual has. Furthermore, those with an agility disability were linked to higher physician costs, while those with a mobility disability were found to have higher medication costs. Both costs were shown to be higher in the case of a psychiatric disability, which was shown to be particularly true for medication costs. These findings highlight the importance of taking into account the type of disability an individual has, when researching healthcare cost drivers.
|
59 |
Health economic assessment of medical technology in chronic progressive diseases : multiple sclerosis and rheumatoid arthritis /Kobelt, Gisela, January 2003 (has links)
Diss. (sammanfattning) Stockholm : Karol inst., 2003. / Härtill 6 uppsatser. ISBN tilldelat efter tryckningen.
|
60 |
Quality, costs and the role of primary health care /Engström, Sven, January 2004 (has links)
Diss. (sammanfattning) Linköping : Univ., 2004. / Härtill 5 uppsatser.
|
Page generated in 0.0702 seconds